Itamar Medical Ltd. (ITMR) Announces Proposed ADS Offering
Get Alerts ITMR Hot Sheet
Join SI Premium – FREE
In a release issued under the same headline on Thursday, February 4th by Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), please note that the contact information was incorrect. The corrected release follows:
Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the commencement of a proposed public offering of American Depositary Shares (“ADSs”) of the Company. Each ADS represents 30 ordinary shares of the Company. The ADSs to be sold in the offering will be offered by the Company and one of its shareholders, Viola Growth 2 A.V. Limited Partnership (the “Selling Shareholder”). The Company and the Selling Shareholder intend to grant to the underwriters a 30-day option to purchase up to an additional 15% of the ADSs being offered on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Piper Sandler, Cowen and SVB Leerink are acting as joint bookrunners for the proposed offering.
The offering will be made only by means of a prospectus supplement and the accompanying prospectuses. A preliminary prospectus supplement related to the offering (including the accompanying prospectuses) will be filed with the SEC and will be available on the SEC’s website located www.sec.gov.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nebius Group closes $5.75B convertible notes offering
- FDA approves Johnson & Johnson drug for rare blood disorder
- FibroBiologics adds sports agent Leigh Steinberg to its board
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share